Development of Synthetic Cell Differentiation Agent Formulations for the Prevention and Therapy of Cancer via Targeting of Cancer Stem Cells

Ming C. Liao1*, Paul A. Fruehauf2, Zhong-Hui Zheng3 and John P. Fruehauf2

1CDA Therapeutics, Tustin, CA, USA
2Division of Research and Development, Xinhua Pharmaceutical Co., Zibo, Shandong, China
3Chao Family Comprehensive Cancer Center, University of California, Irvine Medical Center, Orange, CA, USA

*Corresponding author: Ming C. Liao, CDA Therapeutics, Dr., Tustin, CA, USA; Tel: 8324052660; E-mail: mingliau@yahoo.com

Received: January 05, 2019; Accepted: January 17, 2019; Published: January 29, 2019;

Abstract

The association of methylation enzymes with telomerase constitutes a unique abnormality of cancer cells. This abnormality locks methylation enzymes in an exceptionally stable and active state so that hypomethylation of nucleic acids necessary for the cells to undergo Terminal Differentiation (TD) cannot take place. Human body produces metabolites that are able to eliminate telomerase from abnormal methylation enzymes of cancer cells to allow TD to proceed. Cell Differentiation Agent-2 (CDA-2) is a preparation of human metabolites from freshly collected urine, which has been approved for cancer therapy by the Chinese FDA. The effective components of CDA-2 are Differentiation Inducers (DIs) to target on the telomerase of abnormal methylation enzymes and Differentiation Helper Inducers (DHIs) which are the inhibitors of individual enzymes of ternary methylation enzymes. CDA-2 was very effective for the therapy of Myelodysplastic Syndrome (MDS), which is a disease attributable to Cancer Stem Cells (CSCs). We have previously carried out extensive studies on the DHIs of CDA-2. We are now focusing on the DIs of CDA-2 in order to formulate synthetic CDA for the prevention and therapy of cancer via targeting of CSCs.

DIs were purified from CDA-2 solution by procedures including differential solvent extraction, gel filtration, ion exchange chromatography, TLC, and HPLC. The mass of purified active preparation was determined by mass spectroscopy. DI activity was based on the Nitro Blue Tetrazolium (NBT) assay of HL-60 cells.

DIs of CDA-2 were found predominantly as acidic liposomal complexes extractable by dichloromethane. A good proportion of which became covalently linked to inactive carriers which were not soluble in dichloromethane, but soluble in alcohols. We have identified pregnenolone as a DHI of active liposomal complexes. After dissociation from pregnenolone, the active DIs of CDA-2 were not associated with UV absorption peaks of HPLC. We suspected that the active DIs might be acidic peptides derived from endogenous proteins, because we have previously found that acidic peptides of CDA-2 were active DIs. We, thus, randomly picked pentapeptides containing at least two acidic amino acid residues from the sequences of α- and β-hemoglobin for synthesis to test their DI activities. Indeed, acidic pentapeptides of hemoglobin were active as DIs, although the activities were not impressive. Retinoic Acid (RA) and 12-O-TetradecanoylPhorbol-13-Acetate (TPA) are well known DIs with much better activities.

In this study, we found Pyrvinium Pamoate (PP) as the best DHI, and trinosinate + tetrainosinate (I3 + I1) as an acceptable DHI.

Introduction

Methylation enzymes play a critical role in the regulation of cell replication and differentiation, because DNA methylation controls the expression of tissue specific genes [1] and pre-rRNA ribose methylation controls the production of ribosomes [2], which in turn dictate the commitment of cells to initiate replication [3]. If enhanced production of ribosomes is locked in place, it becomes a factor to drive carcinogenesis [4]. Biological methylation is mediated by a ternary enzyme complex consisting of Methionine Adenosyltransferase (MAT)-Methyltransferase (MT)-S-Adenosyl Homocysteine Hydrolase (SAHH) [5, 6]. These enzymes must be in the ternary enzyme complex to become stable and functional. In
the monomeric state, individual enzymes are quickly inactivated. SAHH is the most unstable enzyme, followed by MT, and then MAT. MTs in the monomeric state have a great tendency to be converted into nuclease to trigger apoptosis. SAHH requires a steroid factor to assume a configuration favorable for the formation of dimeric enzyme complex with MT, which is then in a position to form ternary enzyme complex with MAT. In steroid hormone target tissues such as prostate and breast, steroid hormones are the stabilizing factors of SAHH. Other tissues require similar steroid factors generated by the growth signals to stabilize SAHH [7]. In normal cells, steroid factors are the dominant factors to regulate methylation enzymes. In cancer cells and telomerase expressing primitive stem cells such as embryonic stem cells and progenitor stem cells, MAT is associated with telomerase [8], which becomes the dominant factor to regulate methylation enzymes. The association of MAT1, the low K_m normal isozyme of MAT, with telomerase changes the kinetic properties of MAT1 and the regulation of methylation enzymes. K_m values of MAT1 and MAT1, the telomerase associated tumor isozyme, are 3 μM and 20 μM methionine, respectively, and those of SAHH and SAHH are 0.3 μM and 2 μM adenosine, respectively [5, 6, 8]. The increased K_m value of MAT1 suggests that methylation enzymes of cancer cells have elevated levels of bound S-adenosylmethionine (AdoMet). According to Prudova et al. [9], the binding of AdoMet to a protein could protect that protein against protease digestion. It appears then that the increased pool size of AdoMet in cancer cells is very important for the stability, and therefore the activity of methylation enzymes to promote malignant growth. Chiba et al. [10] found that the pool sizes of AdoMet and S-adenosylhomocysteine (AdoHcy) shrunken greatly when cancer cells were induced to undergo TD. This finding strongly supports our arguments that the association of telomerase with methylation enzymes greatly increase the stability and the activity of methylation enzymes of cancer cells so that hypomethylation of nucleic acids required for the cell to undergo TD cannot take place [6,11]. Thus, it is very convincing that abnormal methylation enzymes play a critical role on the evolution and the progression of cancer.

Association of telomerase with methylation enzymes locks methylation enzymes in extremely stable and active state to block cell differentiation. Telomerase is actively expressed in embryonic stem cells and progenitor stem cells. Differentiation of telomerase expressing normal stem cells will be blocked like cancer cells. There is another way to achieve DNA demethylation bypassing the differentiation blockade created by abnormal methylation enzymes. Tet dioxygenases carry out oxidation of 5 mC to generate 5 hmC, 5 fC and 5 caC [12–15], and 5 caC is finally replaced with C by thymine DNA glycosylase [16,17]. 5 hmC is the stable intermediate in the oxidative demethylation of 5 mC [18]. So far three Tet dioxygenases have been identified. Tet 1 preferentially acts on the 5 mC located at the transcriptional start site, whereas Tet 2 preferentially acts on the 5 mC located in the gene body [19]. Tet 3 is expressed at very high levels in oocytes and zygotes, with rapidly declining at the two cell stage. Tet 3 is responsible for the erase of paternal 5 mC in fertilized oocytes [20]. Tet enzymes are very active in embryonic stem cells to direct extraembryonic lineage differentiation [21,22]. These enzymes are frequently mutated to become dysfunctional or silenced in cancer cells [23–26]. The expression and function of Tet enzymes marks the difference between normal primitive stem cells and cancer cells. Consequently, destabilization of abnormal methylation enzymes is the only option workable to induce TD of cancer cells.

Destabilization of abnormal methylation enzymes is a very effective strategy for cancer therapy. The therapy of acute promyelocytic leukemia (APL) with RA yielded a stunning complete remission around 90% [27]. The remission, however, was only transient. Most patients relapsed within a year, and became resistant to further treatment [28, 29]. A combination of RA and As2O3 produced a more satisfactory long lasting remission [29]. RA is a DI, and As2O3 is a DHI [7]. DI is the chemical capable of eliminating the association of telomerase from abnormal methylation enzymes, and DHI is the inhibitor of individual enzymes of ternary methylation enzymes. It appears then that a combination of DI and DHI is necessary to make a perfect drug for cancer therapy. DHI alone can be very effective for cancer therapy too. After all, human body is producing DIs, although cancer patients are unable to retain such valuable metabolites in the body. Excess DHI can salvage the loss of endogenous DIs. Imatinib mesylate is the standard care for chronic myeloid leukemia [30], which is another good example of effective cancer therapy by destabilization of abnormal methylation enzymes. Signal transduction inhibitors such as imatinib mesylate are excellent DHIs [7]. Phenybutyrate was our creation of the first DHI which was only modestly active requiring mM concentrations to function [31]. Nevertheless, it has demonstrated therapeutic efficacy on often untreatable brain tumors [32,33]. Brain compartment is protected by blood brain barrier. The loss of endogenous DIs is not as severe as other body compartments. Therefore, even modest DHIs can exercise good therapeutic effects. The therapeutic effect of phenylbutyrate was greatly enhanced when it was used in combination with signal transduction inhibitors [34,35], which were much better DHIs effective in μM concentrations [7]. DHIs, such as dietary polyphenols, are frequently suggested for chemoprevention of cancer [36–39].

In 1987, Liau et al. [40] brought up chemosurveillance as a natural defense mechanism against cancer. This hypothesis was based on the observation that healthy people could maintain a steady level of hydrophobic metabolites in their plasma, whereas cancer patients tended to show deficiency of such metabolites due to excessive urinary excretion [41]. Among such metabolites are chemicals capable of inducing cancer cells to undergo TD [42,43]. The evolution of cancer in the case of MDS strongly supports the validity of this hypothesis.

MDS often starts with a display of immunological disorders associated with inflammation [44], which prompts the production of inflammatory cytokines. Among such cytokines, TNF is a critical factor related to the development of MDS [45]. It causes excessive apoptosis of bone marrow stem cells, thus severely affects the ability of the patient to produce hematopoietic cells such as erythrocytes, platelets, and neutrophils. TNF is also named cachectin, because of its involvement in the symptom known as cachexia. Cachexia is a symptom commonly shared by inflammatory patients and cancer patients. A characteristic disorder of cachexia is the excessive urinary excretion of low molecular weight metabolites because of
vascular hyperpermeability cause by TNF [46,47]. As a consequence, chemosurveillance normally operating in healthy people to keep a check on progenitor stem cells is disrupted under pathophysiological conditions created by TNF to allow progenitor stem cells to buildup in order to replenish unipotent stem cells wiped out by TNF. The high levels of telomerase in the peripheral and bone marrow leukocytes in MDS patients is an indication of the widespread multiplication of progenitor stem cells which express telomerase [48,49]. During the course of MDS progression, mutations on Tet2, DNMT3A, IDH1/2, ASXL1, EZH2, and RNA splicing enzymes are frequently observed [50–54], which may play a significant role on the evolution of progenitor stem cells to become CSCs [55]. As anemia symptom becomes worse, chromosomal abnormalities such as translocation and deletion characteristic of cancer cells set in to speed up replication eventually pushing MDS patients to become acute myeloid leukemia patients [56–59].

Vidaza and decitabine are the two hypomethylating agents approved for the therapy of MDS in the USA. CDA-2 is a hypomethylating agent approved by China for the therapy of cancer,[60]. Vidaza and decitabine achieve DNA hypomethylation by promoting covalent bond formation between DNA Methyltransferase (DNMT) and the azacytosine base incorporated into DNA to titrate out DNMT [61], whereas CDA-2 achieves DNA hypomethylation by converting abnormal methylation enzymes into normal enzymes [62,63]. An aborted clinical trial of CDA-2 on MDS was conducted on 117 patients in China. Based on two cycles of treatment protocols, CDA-2 yielded a slightly better therapeutic efficacy under cytological evaluation, and a marked better therapeutic efficacy under hematological improvement evaluation in comparison to vidaza and decitabine,[62, 63]. Apparently CDA-2 had a better therapeutic effect and devoid of serious adverse side effects, whereas decitabine was a proven carcinogen [64]. Since MDS is a disease attributable to CSCs [55], synthetic CDA formulations ought to do well on CSCs.

CSCs constitute only a small subpopulation within a tumor. These cells, nevertheless, are now thought to confer many of adverse characteristics that contribute to treatment failure.[65–69]. Many biological characteristics that enable cancer progression are attributable to CSCs, including angiogenesis, metastasis, recurrence, and drug resistance. Elimination of CSCs is, therefore, very critical to the success of cancer therapy. CSCs are both resistant to cytotoxic chemotherapy and radiotherapy, because these cells overexpress ATP binding cassette drug pumps, and are mostly in dormant state unresponsive to radiation [70–73]. CSCs are equivalent to progenitor stem cells of normal organs or tissues, which replicate only in response to developmental or pathological needs, e.g. growth or wound healing. Thus, CSCs are very responsive to induction of differentiation, which may be the most effective approach to target CSCs.

The objective of this study is to use CDA-2 as a model to develop synthetic CDA formulations for the prevention and therapy of cancer via targeting of CSCs. CDA-2 is a preparation of natural hydrophobic metabolites purified from freshly collected urine by reverse phase chromatograph [74]. We have carried out extensive studies on DHIs of CDA-2 [7,31,74–77]. We are now focusing on DHIs of CDA-2, which are the most important active components of CDA-2. When DHIs becomes available, we will be in a position to solve problems brought up by CSCs.

Methods and Materials

Chemicals and Reagents

Chemicals, chromatographic supplies, and cell culture supplies were purchased from Sigma, St. Louise, MO, unless otherwise indicated. 35x10 mm cell culture dishes were purchased from CytoOne, USA Scientific. Com. Sep-Pak C18 cartridges were purchased from Walters Associates, Milford, MA. Cosmocil C18 column was purchased from Nacalai Tesque, Kyoto, Japan. Acidic pentapeptides were purchased from GenicBio Company of Shanghai, China. 1.5 liter of CDA-2 solution, 304 mg/ml, was a gift of Mr. Zhanji Sun, the general manager of NT Pharmaceuticals, Jiangsu Co. Ltd, China.

Culture of HL-60 Cells

HL-60 cells were purchased from ATCC, Manassas, VI, which were initially maintained in ISOCVE’s modified medium, supplemented with 10% fetal bovine serum, 2 mM glutamine, 50 units/ml penicillin-50 µg/ml streptomycin for a few generations, and then transferred to RPMI 1640 medium to replace ISOCVE’s modified medium. Cells were subcultured every 3 to 4 days at an initial concentration of 5–10 × 10^6 cells/ml.

NBT assay

NBT assay was conducted as previously described [7]. Each 35x10 mm cell culture dish contained 2 ml of RPMI 1640 culture medium. HL-60 cells at an initial concentration of 5–10 × 10^6 cells were incubated with or without drugs for 3 days. Approximately 2.5x10^6 cells were precipitated at 600xg for 5 min. The cell pellet was suspended in 3 drops from a Pasteur pipet of NBT reagent consisting 1 mg NBT and 5 µg TPA per ml Hank balanced salt solution (HBSS), and incubated at 37°C for 30 min. The reaction was terminated by the addition of a drop from a Pasteur pipet of 4% paraformaldehyde in HBSS. NBT + cells were counted under microscope using a hemacytometer.

Determination of potency of DHIs

The potency of DHIs was assessed by the reductive index as previously described [7]. Cell culture dishes were divided into several sets of 5 dishes containing RA of different concentrations to induce between 0 to 60% NBT + . One set had RA alone as control to yield Effective Dosage_{50} (ED_{50}) of RA. Other sets had different concentrations of DHIs together with RA concentrations matching the control set. After incubation at 37°C for 72 h, cell numbers from each dish were counted, and an aliquot was withdrawn for NBT assay as above described. NBT + cells in the control dishes without any drug were always below 1%. In the presence of different DHIs alone, NBT + cells in general were below 10%. The respective control value was subtracted from each experimental value to yield the actual ED value. ED_{50} value, defined as the dosages that induced 50% NBT + cells, were estimated from plots of NBT + values versus concentrations of RA in the absence and presence of DHIs. The Reductive Index (RI) is defined...
as the ED$_{50}$ in the presence of DHI divided by the ED$_{50}$ value of RA alone. The value is inversely related the effectiveness of the DHI agent.

Bio-Gel P2 gel filtration

DIs preparation in less than 4 ml was put onto a Bio-Gel P2 column, 2.5x95 cm for gel filtration resolution. The elution was carried out by 25 mM phosphate buffer, pH 7.8, collecting 4.2 ml/tube/5 min. An aliquot from each tube was withdrawn to dilute with 1 ml of H$_2$O for the determination of A$_{280}$ absorption, and another aliquot was withdrawn from the filtrate of 0.2 µm membrane filter for the determination of NBT$^+$. 

TLC Chromatography

DIs of different K$_a$ fractions from Bio-Gel P2 gel filtration were recovered by C18 cartridge. The fraction was acidified to pH 2.5 and passed the solution through a C18 cartridge. The cartridge was washed twice with 5 ml H$_2$O, and then eluted with 3 ml of 80% methanol. The methanol eluant was evaporated to dryness in a rotary evaporator. The residue was dissolved in a small amount of methanol to apply to a plate of silica gel. The chromatography was developed by ascending chromatography with BuOH-HoAc-H$_2$O (9:2:4) for 8 h to allow the solvent to travel for 17.5 cm from the origin. The silica plate was air dried in a hood overnight. UV images were marked by a pencil. The bands were scraped off the plate with a spatula to put into centrifuge tubes for the extraction with methanol. The methanol extract was evaporated to dryness in a rotary evaporator, and the residue was dissolved in a small amount of methanol for the determination of A$_{280}$ and NBT$^+$. 

Sephadex LH20 Chromatography

A methanol solution of DI subfraction with NaCl concentration less than 25 mM and pH 7.8 was put onto a Sephadex LH20 column, 2.5x36 cm, for chromatography. The elution was carried out by methanol, collecting 2.8 ml/tube/2 min. An aliquot from each tube was withdrawn to dilute with 1 ml of methanol for the determination of A$_{280}$ absorption, and another aliquot was withdrawn for the determination of NBT$^+$. 

DEAE-Sephadex Chromatography

An aqueous solution of DI subfraction with NaCl concentration less than 25 mM and pH 7.8 was put onto a DEAE-Sephadex column, 1.4x27 cm, for chromatography. The column was initially washed with H$_2$O until A$_{280}$ absorption was no longer detectable. The column was then eluted with 160 ml of a linear gradient of NaCl from 0 to 2 M, collecting 4 ml/tube/4 min. An aliquot from each tube was withdrawn to dilute with 1 ml of H$_2$O for the determination of A$_{280}$ absorption, and another aliquot was withdrawn from the filtrate of 0.2 µm membrane filter for the determination of NBT$^+$. 

HPLC

A 50 µl of active DI preparation was injected into a Cosmosil (5C18-RA-II) column, 4.6x250 mm, for HPLC resolution using Hewlett Packard 1050 instrument. The flow rate was set at 0.5 ml/min. The elution during the initial 10 min was carried out by a linear gradient of solution A (5% HoAc) from 100% to 0%, and solution B (80% methanol) from 0% to 100%. Thereafter, the column was eluted with solution B until no more A$_{280}$ absorption was detectable. HPLC fractions were evaporated to dryness in a rotary evaporator. The residue was redissolved in a small volume of methanol for the determination of NBT$^+$.

Mass Spectroscopy

HPLC purified DHI from CDA-2 was injected into LC-MS instrument for the determination of mass.

Results

Purification of DIs from CDA-2 solution

Obviously active DIs and DHIs of CDA-2 are making a significant contribution to protect the vast majority of healthy people from becoming cancer patients. We ought to study these active metabolites which are doing a big favor to benefit human being.

When CDA-2 solution, 304mg/ml, pH 6.7, was acidified to pH 2 with 2N HCl, 32% of A$_{280}$ absorption and almost 100% of DIs were found in the sediment collected by centrifugation at 12000xg for 30 min. The sediment was 50 ml of very dark colored viscous liquid from 1.5 liter of CDA-2 solution. The sediment was first extracted 3 times with 2 volumes of dichloromethane in a flask by shaking overnight each time in a shaker. Dichloromethane extract was the orange solution of the upper phase, which was poured off the flask. Dichloromethane extracted 16.1% of the A$_{280}$ absorption and 37.6% of the DI activity from the pH 2 sediment of CDA-2 solution. Next, the remaining sediment was dissolved in 5 volumes of methanol, and insoluble materials were removed by centrifugation at 12000xg for 30 min. Methanol extracted 69.7% of the A$_{280}$ absorption and 60% of the DI activity from the pH 2 sediment of CDA-2 solution. Methanol insoluble residue was dissolved in dilute NaOH solution, and pH adjusted to 7.8, which constituted 14.1% of the A$_{280}$ absorption and 2.4% of the DI activity of the pH 2 sediment of CDA-2 solution. DIs soluble in dichloromethane are very hydrophobic metabolites and DIs soluble in methanol are less hydrophobic.

Gel filtration profiles of DIs on Bio-Gel P2 column chromatography

Organic solvents of DI extracts were removed by rotary evaporator at temperature below 60°C. The residues were dissolved in dilute NaOH solution and pH adjusted to 7.8. 4 ml aliquot from each preparation containing approximate 100,000 A$_{280}$ absorption units was put on a column of Bio-Gel P2 column for gel filtration as described in Methods and Materials. Dichloromethane extractable DIs have two major peaks at K$_a$ = 0.43 and 0.52, and a minor peak at K$_a$ = 1.45 as shown in Fig. 1. K$_a$ = 0.43 and 0.52 are quite large molecular weight complexes.

Gel filtration profile of methanol extractable DIs is presented in Fig. 2. Methanol extractable DIs have a major peak at K$_a$ = 0 and two minor peaks at K$_a$ = 0.43 and 0.52 which are probably the major components of dichloromethane extractable DIs. DIs of K$_a$ = 0 are even bigger than those of dichloromethane extractable DIs.
**Figure 1.** Gel filtration profile of the dichloromethane extractable DIs of CDA-2

4 ml of dichloromethane extractable DIs of CDA-2 containing approximately 100,000 A$_{280}$ absorption units were put onto a column of Bio-Gel P2 column for gel filtration as described in Methods and Materials.

**Figure 2.** Gel filtration profile of the methanol extractable DIs of CDA-2

4 ml of methanol extractable DIs of CDA-2 containing approximately 100,000 A$_{280}$ absorption units were put onto a column of Bio-Gel P2 column for gel filtration as described in Methods and Materials.
The dark solution of the Kav = 0 of methanol extractable DIs produced scale-like dark precipitate and clear light color solution when the pH was acidified to 2 with 2N HCl. DI activities became dissociated from the dark inactive carrier when the precipitate was dissolved in 0.5N NaOH and incubated at 37°C as shown in Fig. 3.

The major DI peak shifted from Kav = 0 to Kav = 0.09 after incubation at 37°C for 0.5 h, and then to Kav = 0.43 and 0.52 after incubation for 24 h. The Kav = 0.43 and 0.52 DIs were extractable by dichloromethane when the solution was acidified to pH 2. It appears then that DIs of Kav = 0.43 and 0.52 are the major DIs of CDA-2. A good proportion of these DIs becomes covalently linked to the inactive carrier of Kav = 0 previously identified as pigment peptides.[43].

TLC chromatography of dichloromethane extractable DIs of CDA-2

Dichloromethane extractable DIs of CDA-2 from Fig. 1 were recovered by C18 cartridges and resolved by TLC as described in Methods and Materials. Result is presented in Table 1. Significant DI activities were widespread detectable from Rf = 0.15 to 0.92. Similar widespread activities were also found on DIs of Kav = 0.52. The only difference was the relative activity of different Rf bands. DIs of Kav = 0.43 had more DIs with higher Rf values. DIs of Kav = 1.45 were much simpler. Rf = 0.57 band stood out as the only major active band. TLC data serve to indicate that DIs of Kav = 0.43 and 0.52 are complexes of multiple different DIs or a few limited DIs in association with multiple different DHIs or inactive materials.

<table>
<thead>
<tr>
<th>Rf</th>
<th>UV images</th>
<th>A280/ml</th>
<th>% Growth</th>
<th>% NBT+</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.95</td>
<td>Bright blue fluorescent</td>
<td>0.05</td>
<td>73</td>
<td>5.8</td>
</tr>
<tr>
<td>0.92</td>
<td>Gold fluorescent</td>
<td>0.16</td>
<td>59</td>
<td>22.8</td>
</tr>
<tr>
<td>0.86</td>
<td>Dark absorption</td>
<td>0.23</td>
<td>77</td>
<td>7.4</td>
</tr>
<tr>
<td>0.81</td>
<td>Gold fluorescent</td>
<td>0.21</td>
<td>54</td>
<td>15.8</td>
</tr>
<tr>
<td>0.74</td>
<td>Gold fluorescent</td>
<td>0.23</td>
<td>68</td>
<td>5.3</td>
</tr>
<tr>
<td>0.62</td>
<td>Gold fluorescent</td>
<td>0.19</td>
<td>90</td>
<td>11.6</td>
</tr>
<tr>
<td>0.57</td>
<td>Dark absorption</td>
<td>0.16</td>
<td>81</td>
<td>44.0</td>
</tr>
<tr>
<td>0.44</td>
<td>Bright blue fluorescent</td>
<td>0.15</td>
<td>47</td>
<td>17.5</td>
</tr>
<tr>
<td>0.34</td>
<td>Multiple narrow gold</td>
<td>0.10</td>
<td>61</td>
<td>17.9</td>
</tr>
<tr>
<td>0.15</td>
<td>Weak gold fluorescent</td>
<td>0.05</td>
<td>73</td>
<td>11.5</td>
</tr>
<tr>
<td>0.08</td>
<td>Very weak gold fluorescent</td>
<td>0.05</td>
<td>85</td>
<td>4.3</td>
</tr>
</tbody>
</table>

Methanol solution of Kav=0.43 DIs of Fig. 1 was applied to a TLC plate for chromatography as described in Methods and Materials.

Sephadex LH20 Chromatography

DIs of Kav = 0.43 and 0.52 from Fig. 1 were recovered by C18 cartridges as above described. 4 ml of methanol solution containing approximately 25,000 A280 absorption units were put on a column of Sephadex LH20 column for chromatography as described in Methods and Materials. The chromatographic profile is shown in Fig. 4. Two active peaks similar to two Bio-Gel P2 peaks of Kav = 0.43 and 0.52 were found, one eluted between 150–180 ml, and the other between 180–210 ml. The separation of two peaks on Sephadex LH 20 chromatography appeared more clean cut than those on Bio-Gel P2 gel filtration. The active fractions of two peaks were pooled separately, and methanol was removed by rotary evaporator. The residue of each
active fractions was suspended in 5 ml H$_2$O, and 1N NaOH was added dropwise to bring pH up to 7.8 to dissolve the residue. NaOH soluble material gave rise to a total of 11,500 A$_{280}$ absorption units from 150–180 ml peak, and 5,500 A$_{280}$ absorption units from 180–210 ml peak. These preparations were separately put on a column of DEAE-Sephadex for chromatography as described in Methods and Materials. DEAE-Sephadex chromatographic profiles are shown in Fig. 5 and 6. The 150–180 ml peak of Sephadex LH20 chromatography gave rise to two active fractions eluted between 0.55–0.75 M NaCl as a major peak and between 0.85–1.05 M NaCl as a minor shoulder peak. The 180–210 ml peak of Sephadex LH 20 chromatography produced a reverse profile: a minor shoulder peak between 0.55–0.75 M NaCl and a major peak between 0.85–1.05 M NaCl. When DEAE-Sephadex chromatographic fractions were stored at 4°C for more than 1 week, noticeable precipitate was found in active fractions from 0.55–1.05 M NaCl. The precipitate was inactive as DIs. The DI activity of the supernatant declined greatly to 22% of the original activity, which was restored to almost the original activity when enough precipitate redissolved in methanol was added back. Thus, the precipitate fits the description as DHI [31]. Upon purification by HPLC, the precipitate yielded a major UV peak at RT-19.1. The eluant of the RT-19.1 peak was evaporated to dryness by rotary evaporator, and redissolved in a small volume of methanol. Subsequent HPLC analysis showed a single RT-19.1 peak as shown in Fig. 7. The mass determination of the RT-19.1 HPLC peak of Fig. 7 yielded a mass of 316.118 as shown in Fig. 8. This mass is very close to the mass of pregnenolone, which is 316.48.

Figure 4. Sephadex LH20 chromatography of K$_{av}=0.43 + 0.52$ pooled material of Fig. 1

K$_{av}=0.43 + 0.52$ of Fig. 1 were recovered by C18 cartridges as described in Methods and Materials. The residue was dissolved in methanol. 4 ml of methanol solution containing approximately 25,000 A$_{280}$ absorption units were put on a column of Sephadex LH20 for chromatography as described in Methods and Materials. Two fractions eluted between 150–180 ml and 180–210 ml were separately pooled, and methanol was removed by rotary evaporation under vacuum.
The residue of the 150–180 ml peak of Fig. 4 was dissolved in dilute NaOH, and pH adjusted to 7.8. 5 ml of this solution containing a total of 11,500 A$_{280}$ absorption units were put onto a column of DEAE-Sephadex for chromatography as described in Methods and Materials. Active fractions eluted between 0.55–0.75 M NaCl and 0.85–1.05 M NaCl were separately pooled.

**Figure 5.** DEAE-Sephadex chromatography of the 150–180 ml peak of Sephadex LH20 chromatography

The residue of the 180–210 ml peak of Fig. 4 was dissolved in dilute NaOH, and pH adjusted to 7.8. 5 ml of this solution containing a total of 5,500 A$_{280}$ absorption units were put onto a column of DEAE-Sephadex for chromatography as described in Methods and Materials. Active fractions eluted between 0.55–0.75 M NaCl and 0.85–1.05 M NaCl were separately pooled.

**Figure 6.** DEAE-Sephadex chromatography of the 180–210 ml peak of Sephadex LH20 chromatography
Confirmation of the HPLC RT-19.1 peak of CDA-2 as pregnenolone

Pregnenolone obtained from Sigma was dissolved in methanol to make 1.5 mg/ml, namely 4.74 mM. The A280 absorption is very low, which is 0.054/mM. The solution gave a HPLC peak at RT-19.1. When RT-19.1 peak of CDA-2 was mixed with Sigma pregnenolone, the mixture gave a single peak at RT-19.1. The potency of the HPLC RT-19.1 of CDA-2 as DHI was exactly the same as that of Sigma pregnenolone as previously reported, namely 7.16 µM. It is obvious that pregnenolone is a component of active liposomal DIs of CDA-2.

Acidic pentapeptides of hemoglobin as DIs

We have tried to capture DIs in the supernatant of DEAE-Sephadex active eluants. The significant A280 absorption peaks of HPLC were all inactive as DI. We thus concluded that DIs of CDA-2 might not have A280 absorption. We have previously found that acidic peptides of the urine were active DIs [42]. We had reason to believe that plasma and urinary peptides were primarily the degradative products of endogenous proteins, because peptide profiles among different persons were similar, and those profiles were most close to the peptide profile of the spleen extract [40,41]. It is well known that erythrocytes are constantly turning over, and spleen is the organ to degrade dead erythrocytes. We assumed that the active acidic peptide of CDA-2 might be the degradative products of hemoglobin. Taking cue from the discovery of an acidic pentapeptide to modulate hemopoiesis by Laerum and Paukovits [78], we randomly picked pentapeptides containing at least two acidic amino acid residues from the sequences of α- and β-hemoglobin for synthesis to test their activities as DIs. Indeed, acidic pentapeptides of hemoglobin were active as DIs as shown in Table 2, although the activities were only modest.

Table 2. DI activity of synthetic acidic pentapeptides

<table>
<thead>
<tr>
<th>Designation</th>
<th>Sequence</th>
<th>ED25 µM</th>
</tr>
</thead>
<tbody>
<tr>
<td>5P-1</td>
<td>Ala-Glu-Ala-Leu-Glu</td>
<td>122±32</td>
</tr>
<tr>
<td>5P-2</td>
<td>Val-Asp-Glu-Val-Gly</td>
<td>154±28</td>
</tr>
<tr>
<td>5P-3</td>
<td>Val-Asp-Asp-Met-Pro</td>
<td>174±55</td>
</tr>
<tr>
<td>5P-4</td>
<td>Asp-Pro-Glu-Asp-Phe</td>
<td>207±42</td>
</tr>
<tr>
<td>PA-5P-4</td>
<td>PA-Asp-Pro-Glu-Asp-Phe</td>
<td>161±33</td>
</tr>
<tr>
<td>5P-5</td>
<td>Pro-Glu-Glu-Lys-Ser</td>
<td>415±76</td>
</tr>
</tbody>
</table>

Synthetic acidic pentapeptides were dissolved in 80% methanol for the test of DI activity. The dosages were selected to give ED between 20 and 30% NBT + . ED25 was obtained from the plots, and expressed as mean±S. D. from at least two experiments. The combination of RA and acidic pentapeptides produced additive effect, whereas the combination of RA and DHIs produced synergistic effect as previously reported [7,31,76,77].

RA is a well known DI, which requires retinoic acid receptor (RAR) to activate oligoisoaadenylate synthetase [79], and the product of this enzyme, oligoisoaadenylate, is the responsible DI to initiate differentiation induction [6]. Oligoisoaadenylate has to be synthesized inside the cell to function, because 5’ terminal triphosphate prohibits it to be absorbed from outside. Therefore, RA is only effective on cells expressing RAR. RARs are expressed on developmental stages of embryonic cells [80], in pluripotent stem cells to regulate organ and limb development [81], in CSCs [82–84], and in certain cancers such
as APL [27], acute myeloid leukemia [85], neuroblastoma [86], breast cancer [87], and melanoma [88].

TPA is another well known DI, which acts as DI in some cells, but as differentiation inhibitor in other cells depending on which molecules are being affected, or as tumor promotor by increasing cell multiplication in initiated cells [89]. Biological effects of TPA are mediated through initial interaction with membrane [90]. Therefore, TPA affects almost all cancers. The tumor promotion activity of TPA can be effectively cancelled by DHIs [91]. Despite its adverse effects, TPA has been put through clinical trials for the evaluation as a cancer drug [92–94]. TPA had a very impressive DI activity on HL-60 cells as shown in Fig. 9. The maximum activity was at 0.4 nM to induce 92% NBT + . At this concentration 90% of cells were attached to the culture dish. Above this concentration, cell growth was greatly inhibited, and NBT + cells declined precipitously. ED_{25} of TPA was 0.17 ± 0.02 nM when tested on fast growing HL-60 cells. The growth rates measured by N3/N0 were between 13.7–15.4, almost 3 to 4 generations in 3 days. ED_{25} of RA was 1.17 ± 0.16 µM tested on HL-60 cells with growth rates same as those of TPA. We have previously found that HL-60 cells responded better to RA when grew slower at earlier passages. ED_{25} of RA was 0.78 µM when tested on HL-60 cells with N3/N0 between 6.3–7.5.

**Figure 9. DI activity of TPA**

TPA was dissolved in methanol which was added to the culture in the amounts indicated. The volume of methanol was less than 2%. NBT assay was conducted as described in Methods and Materials.

**Potential DHIs for synthetic CDA formulations**

We have previously shown that RA alone could not push all HL-60 cells to complete TD [7]. 95% NBT + cells was the maximum extent achieved by RA. But in the presence of DHIs, the extent of NBT + cells could reach 100% [7]. 92% NBT + cells was the maximum extent reached by TPA in this study. Cells unable to undergo differentiation in the presence of DI alone are the cells damaged enough to prevent completion of two replication cycles needed for TD. The damaged cells if repaired become the roots for recurrence. Removal of the possible recurrent roots by DHIs is another important contribution of DHIs. The most serious damage that can be attributed to DIs are the promotion of the dissociation of methylation enzymes, and the conversion of the monomeric MTs into nucleases. MT inhibitors can effectively prevent such conversion. Uroerythrin was a good MT inhibitor to function as the most active DHI of CDA-2 [77]. This chemical is not commercially available. We need to find substitutes to prevent damages created by DIs alone. We have previously found that I3 and I4 from limited alkaline hydrolysis of poly I were potent inhibitors of nucleolar rRNA methyltransferase [2]. We, thus, prepared I3 + I4 and A3 + A4 as previously described [2] to test their DHI activities. Results shown in Table 3 indicate that I3 + I4 and A3 + A4 are active as DHIs. Included in Table 3 is PP as the most active DHI we have discovered so far. PP has been shown active as signal transduction inhibitor and inhibitor of androgen receptor,[95–98]. Both classes of inhibitors are excellent DHIs [7]. The superb activity of PP as DHI may be attributable to its dual activities to inhibit signal transduction and steroid receptor.
Development of synthetic CDA formulations for the prevention and therapy of cancer via targeting of CSCs

CDA-2 was effective to eliminate CSCs subpopulation [99,100], and had a very effective therapeutic efficacy on MDS [62, 63], a disease attributable to CSCs. Our immediate objective is to develop synthetic CDA formulations for the therapy of MDS, CSCs, and cancers in which CSCs play a dominant role on the pathological features and drug responses of the diseases. Cancers originated from progenitor stem cells such as MDS above described and acute myeloid leukemia resulting from MDS are enriched in CSCs. Evidence indicates that brain tumors are also originated from progenitor stem cells [101,102]. Melanoma and pancreatic cancer may not originate from progenitor stem cells, but these cancers express high levels of factors such as hypoxia inducible factors and NF-kB which can effectively drive EMT to display CSC phenotype [103 -106]. On MDS, protection of pathological cells is a necessity, because the therapy requires the differentiation of pathological cells to become functional erythrocytes. DIs and DHIs of low toxicity are preferred. On other CDA formulations, destruction of pathological cells is a preferred choice. On CSCs, toxicity is also a big concern, because CSCs naturally reject toxic chemicals. CSCs are situated in hypoxic microenvironment hard to reach by the blood, small molecules with penetration power are preferred. On brain tumor, blood brain barrier must be the major concern. Hydrophobic chemicals have better chance to cross that barrier. For melanoma and pancreatic cancer, potent DIs and DHIs are preferred. CDA formulations must consist of both DIs and DHIs to make perfect drugs. The following formulations are acceptable formulations: 3xED, of DI + 1xRI of DHI; 2xED of DI + 2xRI of DHI; or 1xED of DI + 3xRI of DHI. 1xRI of DHI is equivalent to 1xED of DI [7]. The multiplicity of DI can be multiplicity of a single DI, or a combination of different DIs. Likewise, the multiplicity of DHI can be multiplicity of a single DHI, or a combination of different DHIs.

Our deliberated CDA formulations are listed in table 4. CDA-MDS, CDA-BT (brain tumor), and CDA-M&P (melanoma and pancreatic cancer) are parenteral preparations, and CDA-CSC is an oral preparation which is designed for long term application to prevent recurrence after active therapy. Thus, an oral preparation is a practical drug form. On active cancer therapy, CDA-CSC is best used in combination with drugs to inhibit growth factor receptors and signal transductions, or drugs for anti-steroid hormonal therapy.

These drugs are actually good DHIs. It is also compatible with other therapeutic modalities to target on different entities, e.g. CDA-CSC to target on CSCs and cytotoxic drugs or radiation to target on non-CSCs. TPA and PP are not soluble in H2O. RA, resveratrol, and curcumin are not very soluble in H2O. Dispensing aids such as liposomal and nanoparticle technologies must be employed to increase bioavailability for clinical application. Phenylacetylglutamine [PAG] is a major chemical constituent of CDA-2, which is also very useful to extend bioavailability of DIs and DHIs. We recommend to include 2 mM PAG in each CDA formulation for the purpose of extending bioavailability of DIs and DHIs and to cancel tumor promotion activity of TPA.

We have previously shown that PAG, namely Antineoplastic A10, was effective to prevent the loss of low molecular weight metabolites including active DIs and DHIs [40]. By preventing the loss of endogenous DIs and DHIs, PAG was effective to prevent carcinogen-induced pulmonary neoplasia and hepatoma [107,108], and to achieve therapy of early stage cancer [40]. PAG is a very effective deterrent of tumor promoters. PAG is synthesized from phenylacetyl chloride and glutamine as previously described [76]. CDA formulations listed in Table 4 are plasma concentrations to achieve induction of TD of HL-60 cells above 100% on purpose to achieve maximum therapeutic effect. Multiplication of these amounts per liter of blood by a factor of 5, which is the normal blood volume of a person of 80 Kg body weight, is necessary to produce an effective dosage. Application of 3 effective dosages a day should give satisfactory therapy.

Table 3. Potential DHIs for synthetic CDA formulations

<table>
<thead>
<tr>
<th>Designation</th>
<th>Formulation</th>
<th>% Growth</th>
<th>%NBT+</th>
</tr>
</thead>
<tbody>
<tr>
<td>CDA-MDS</td>
<td>RA(ED3)-SP-1(ED2)-I-R(RI)-PP(RI)-Na pregnenolone SO4(RI)</td>
<td>77 ± 5.2</td>
<td>100</td>
</tr>
<tr>
<td>CDA-CSC</td>
<td>RA(ED3)-TPA(ED3)-PP(RI)-resveratrol(RI)-curcumin(RI)</td>
<td>53 ± 3.6</td>
<td>100</td>
</tr>
<tr>
<td>CDA-BT</td>
<td>TPA(2xED3)-PP(2xRI)-Na phenylbutyrate(RI)-pyrogallol(RI)</td>
<td>45 ± 3.9</td>
<td>100</td>
</tr>
<tr>
<td>CDA-M&amp;P</td>
<td>TPA(2xED3)-SP-1(ED3)-PP(2xRI)-Na tannate(RI)</td>
<td>33 ± 4.4</td>
<td>100</td>
</tr>
</tbody>
</table>

CDA-MDS is a parenteral preparation as a monotherapy of MDS. CDA-CSC is an oral preparation for use in combination with other drugs. CDA-BT is a parenteral preparation as a monotherapy of brain tumor. CDA-M&P is also a parenteral preparation as a monotherapy for melanoma and pancreatic cancer.

DIs and DHIs were methanol solution except 5P-1 which was in 80% methanol, and Na phenylbutyrate which was in H2O solution. Each component was added individually. RA(ED3) is 1.17 µM, SP-1(ED3) is 122 µM, I-R(RI) is 3.7 µM, PP(RI) is 12.2 nM, TPA(ED3) is 0.17 nM, resveratrol (RI) is 1.16 µM, curcumin(RI) is 1.24 µM, Na phenylbutyrate(RI) is 2 mM, and Na tannate(RI) is 0.37 µM as previously reported,[7] or shown in this paper. NBT assay was carried out as described in Methods and Materials.

Discussion

Abnormal methylation enzymes are an important issue of cancer. Almost all human cancers display such an abnormality [8,109]. Abnormal methylation enzymes are the critical factor responsible for the blockade of differentiation of cancer cells [6].


Table 4. Synthetic CDA formulations

expression of telomerase fits the first hit of Knudson’s two hits theory [110]. Telomerase is also expressed in primitive stem cells such as embryonic stem cells and progenitor stem cells. Evidently blockade of differentiation is a normal biological process to build up cell mass for the development of fetus, or wound healing. The blockade of differentiation in these normal stem cells does not create problem, because Tet enzymes are functioning which can break through the blockade created by abnormal methylation enzymes to spearhead differentiation programs. The problem arises if Tet enzymes become dysfunction due to mutation or silencing such as the case of MDS [23–26]. The loss of Tet enzymes becomes the second hit of Knudson’s theory. Therefore, the evolution of cancer in the case of MDS is a perfect interpretation on the validity of the two hits theory of Knudson [110], and our chemosurveillance hypothesis [40].

Progenitor stem cells and CSCs are almost indistinguishable with only very minor differences, the functionality of Tet enzymes being a significant difference between them. Progenitor stem cells are very likely the origin of most human cancers, not just acute myeloid leukemia resulting from MDS or brain tumors. We have detected abnormal methylation enzymes to function actively in preneoplastic hyperplastic nodules induced by hepatocarcinogen [111]. Therefore, progenitor stem cells are just like time bombs, and natural DIs and DHIs are the safety devices to keep them from evolving into CSCs.

Chemicals extractable by dichloromethane are in general very hydrophobic. The detection of pregnenolone as a component of DIs of CDA-2 is a certain indication that active DIs of CDA-2 is liposomal complexes. The release of liposomal-like DIs from methanol extractable DIs by NaOH hydrolysis suggests that dichloromethane extractable DIs and methanol extractable DIs are basically the same liposomal complexes. A large proportion of these liposomal complexes become covalently linked to the inactive carrier previously identified as pigment peptides [40] either by enzymatic dehydration in the body or due to heat pyrolysis during evaporation of ethanol eluant in the process of CDA-2 preparation. The inactive pigment peptide carrier is very likely fragments of membrane. The liposomal DIs of $K_w = 0.43$ and 0.52 are stable in methanol, ethanol, and dichloromethane, but are not stable in butanol or high salt solution. DIs in free forms do not seem to have $A_{280}$ absorption. Without $A_{280}$ absorption as a probe, it is very difficult to capture DIs of CDA-2. The real DIs of CDA-2 are still up in the air.

We have identified pregnenolone as a DHI of CDA-2 in this study. Pregnenolone is the master substrate of all biologically active steroids, which is synthesized from cholesterol absorbed from diet or produced in the liver. The peak age of the production of pregnenolone is 20 years old, producing approximately 50 mg a day, [112]. The very young and the very old are the two age groups producing the least amount of pregnenolone. These are the two age groups most susceptible to cancer. Fortifying effective DHIs definitely is a good policy to amend natural insufficiency.

The therapy of APL with RA sets a classical example of the effectiveness of destabilization of abnormal methylation enzymes on cancer therapy [27]. RA alone is very effective, but imperfect. Recurrence ensues quickly [28]. This is because RA alone causes the dissociation of abnormal methylation enzymes too extensive to contribute to nuclease activity which creates damages to interrupt differentiation process. This phenomenon is analogous to the antiviral effect of interferon. Interferon is actually a DI like TPA to activate oligoisoadenylate synthetase through interaction with membrane. The product of oligoisoadenylate synthetase is a potent activator of latent nucleases to execute antiviral effect. The damage created by DI alone may affect only a small fraction of cells in the S phase when DNA is most susceptible to nuclease attack. The damages interrupt differentiation process, but when damaged cells are repaired later they become the roots for recurrence. Damages by DI alone can be prevented by DHIs. MT inhibitors can prevent protease modification to turn MT into nuclease. Steroids analogs are even better, which keep MT in dimeric complex with SAHH to protect the integrity of MT. The protection of MT from becoming nuclease is the cause that DHI is an essential partner of a perfect cancer drug.

The option for the eradication of cancer stem cells is very limited. The ideal therapeutic agents must be small molecules that are relatively non-toxic to bypass drug efflux pumps to reach adequate intracellular concentrations to trigger cancer stem cells to undergo differentiation. Synthetic CDA formulations are an attractive strategy to eradicate cancer stem cells. DIs is the most important components of CDA formulations. The choices of DIs are very limited; RA is only effective in cancers expressing RAR. TPA is universal, but is very toxic. 5Ps are universal, but are not very active. The requirement of DI is to initiate TD to reach a level above 15%, the rest can be accomplished by DHIs [7]. Therefore, even though 5Ps are not very active, they can be remedied by very active DHIs such as PP. We have developed many excellent DHIs to choose from. The mere application of effective DHIs can have excellent therapeutic effect on cancer as exemplified by imatinib mesylate. The brain compartment is a unique compartment protected by blood brain barrier, which also protect the loss of endogenous metabolites. Therefore, the deficiency of endogenous DIs and DHIs is not as severe as other body compartments. That is why DHIs have impressive therapeutic effect on brain tumor.

Destabilization of abnormal methylation enzymes is a good policy to implement at the earliest diagnosis of cancer to avoid aberrant DNA methylation no matter what cancer therapy is to follow. Aberrant DNA methylations are frequently detected in advanced cancer, which can turn ordinary responsive cancer to become very vicious cancer unresponsive to any treatment. Aberrant DNA methylations happen more readily when DNA synthesis is slowing down by cytotoxic drugs or radiation [113]. Another benefit to implement destabilization of abnormal methylation enzymes is to avoid expansion of CSC population induced by the destruction of the tumor caused by cytotoxic chemotherapy [114], or due to tumor progression [103–106]. Reconstruction of the tumor is a major mission of CSCs. Therefore, destabilization of abnormal methylation enzymes is a very good strategy to pursue for cancer therapy.

Acknowledgement

This study was supported in part by a contract awarded to CDA Therapeutics, Inc. by Xinhua Pharmaceutical Company of Zibo, Shandong China. We are indebted to the gift of CDA-2 solution from...
Mr. Zanji Sun of NTPharma of Tai Zhou, Jiangsu, China. We are very grateful to Christian Brower for the art work of figures.

Funding Information
The funder had no involvement in the study design; in the collection, analysis and interpretation of the data; in the writing of the report, and in the decision to submit the paper for publication. The funder had an active supervising role.

References


**Citation:**